On July 7, 2021 Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled "Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors" at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET (Press release, Replimune, JUL 7, 2021, View Source [SID1234584660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.